Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Prometheus Biosciences stock

Learn how to easily invest in Prometheus Biosciences stock.

Prometheus Biosciences is a biotechnology business based in the US. Prometheus Biosciences shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences employs 72 staff and has a trailing 12-month revenue of around $7.2 million.

How to buy Prometheus Biosciences stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – RXDX. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Prometheus Biosciences stock price (NASDAQ: RXDX)

Use our graph to track the performance of RXDX stocks over time.

Prometheus Biosciences shares at a glance

Information last updated 2023-01-25.
Latest market close$113.66
52-week range$21.50 - $122.75
50-day moving average $86.85
200-day moving average $51.80
Wall St. target price$146.18
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.78

Buy Prometheus Biosciences stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Prometheus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Prometheus Biosciences price performance over time

Historical closes compared with the close of $113.66 from 2023-01-31

1 week (2023-01-25) -4.58%
1 month (2022-12-30) 3.33%
3 months (2022-11-02) 122.43%
6 months (2022-08-02) 172.11%
1 year (2022-02-02) 216.43%
2 years (2021-01-29) N/A
3 years (2020-01-29) N/A
5 years (2018-01-29) N/A

Prometheus Biosciences financials

Revenue TTM $7.2 million
Gross profit TTM $-59,298,000
Return on assets TTM -27.21%
Return on equity TTM -53.74%
Profit margin 0%
Book value $5.56
Market capitalisation $5.5 billion

TTM: trailing 12 months

Prometheus Biosciences share dividends

We're not expecting Prometheus Biosciences to pay a dividend over the next 12 months.

You may also wish to consider:

Have Prometheus Biosciences's shares ever split?

Prometheus Biosciences's shares were split on a 1:100 basis on 31 October 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Prometheus Biosciences shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Prometheus Biosciences shares which in turn could have impacted Prometheus Biosciences's share price.

Prometheus Biosciences overview

Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc.

Frequently asked questions

What percentage of Prometheus Biosciences is owned by insiders or institutions?
Currently 19.172% of Prometheus Biosciences shares are held by insiders and 73.341% by institutions.
How many people work for Prometheus Biosciences?
Latest data suggests 72 work at Prometheus Biosciences.
When does the fiscal year end for Prometheus Biosciences?
Prometheus Biosciences's fiscal year ends in December.
Where is Prometheus Biosciences based?
Prometheus Biosciences's address is: 9410 Carroll Park Drive, San Diego, CA, United States, 92121
What is Prometheus Biosciences's ISIN number?
Prometheus Biosciences's international securities identification number is: US74349U1088

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site